Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Lippoldt Darin sold 10,000 Neurocrine Biosciences, Inc. shares (Form 4)
Traded Jun 26 to Jun 29, 2026 · Filed Jun 30, 2026
From Jun 26 to Jun 29, 2026, Lippoldt Darin (Chief Legal Officer) sold 10,000 Neurocrine Biosciences, Inc. shares at an average US$170.15 for US$1.7M under a trading plan, leaving 54,729 shares. Filed Jun 30, 2026 (Form 4).
- Sold
- 10,000 shares
- Price
- US$170.15 average (US$169.57 to US$170.81)
- Value
- US$1.7M
- Holding after
- 54,729 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Legal Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | Option exercise | 200 | US$81.49 | 54,929 | Direct |
| Jun 26, 2026 | Common Stock | Sale | 200 | US$169.57 | 54,729 | Direct |
| Jun 29, 2026 | Common Stock | Option exercise | 8,110 | US$81.49 | 62,839 | Direct |
| Jun 29, 2026 | Common Stock | Sale | 8,110 | US$170.03 | 54,729 | Direct |
| Jun 29, 2026 | Common Stock | Option exercise | 1,690 | US$81.49 | 56,419 | Direct |
| Jun 29, 2026 | Common Stock | Sale | 1,690 | US$170.81 | 54,729 | Direct |
Source
Related
- Neurocrine Biosciences, Inc.
- Lippoldt Darin
- Neurocrine Biosciences, Inc. shareholders
- Form 4 · Lippoldt Darin · Sep 15, 2026
- Form 4 · Lippoldt Darin · Jul 13, 2026
- Schedule 13G/A · JPMorgan Chase & Co · Oct 15, 2026
- Form 4 · Boyer David W. · Sep 15, 2026
- Form 4 · Abernethy Matt · Sep 15, 2026
- Form 4 · Gano Kyle · Sep 15, 2026
- Form 4 · Onyia Jude · Sep 15, 2026